Sponsor content

Therapy for genetically defined orphan inflammatory disease

AnaptysBio’s monoclonal-antibody approach—currently in preclinical development—may provide a therapeutic option for generalized pustular psoriasis. To download the full article, please sign in.

Go to the profile of AnaptysBio Inc
Nov 05, 2015
1
Page of
Go to the profile of AnaptysBio Inc

AnaptysBio Inc

AnaptysBio is a leading biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. We develop our product candidates using our proprietary antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Our platform is based upon a breakthrough understanding of somatic hypermutation, the key biological process utilized to generate antibodies, which enables us to rapidly develop highly functional antibody drug candidates against emerging biological targets.

Comments are disabled